Apollo People

Melanie Glossop

Apollo Therapeutics Project Director

Melanie Glossop

Mel joined Apollo in February 2020 and has brought a wealth of experience to the team in chemistry previous to Apollo Mel was Head of Chemistry for Centauri Therapeutics Limited, responsible for the strategy, delivery and execution of the Centauri chemistry immunotherapy portfolio across a range of chemical disciplines including aptamers, peptides, carbohydrates and antibodies. Mel established a diverse patent portfolio leading to both private and public investment, underpinning the Centauri linker platform. In 2017 she was listed as one of 10 Movers and Shakers in UK BioBusiness for Great Science (BioBeat 2017). Prior to Centauri Mel led the chemistry programme for Agalimmune, enabling the synthesis and scale-up of the lead asset from discovery through to CMC. Prior to this, Mel spent 17 years at Pfizer, leading multiple global chemistry teams, both in-house and externally to enable delivery of molecules from hit-to-lead through to candidate-nomination and development. Mel is a Fellow of the Royal Society of Chemistry and is currently serving as a member of the RSC’s Professional Standards Board